A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemiaLena Golick(Medical University of South Carolina), Nathan G. Dolloff(Io Therapeutics (United States))Blood Cancer JournalNovember 17, 202510.1038/s41408-025-01391-wCited by 0SaveCiteExport RISWatch citationsRelated PapersPharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma|Biomolecules|2025|0A superantigen-based MHC class II targeted cancer immunotherapy for the treatment of acute myeloid leukemia|Research Square|2025|0